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ABSTRACT
Chronic disease progression models are governed by three main parameters: sensitivity, preclini-
cal intensity, and sojourn time. The estimation of these parameters helps in optimizing screening
programs and examine the improvement in survival. Multiple approaches exist to estimate those pa-
rameters. However, these models are based on strong underlying assumptions. The main aim of this
article is to investigate the effect of these assumptions. For this purpose, we developed a simulator
to mimic a breast cancer screening program directly observing the exact onset and the sojourn time
of the disease. We investigate the effects of assuming the sensitivity to be constant, inter-screening
interval and misspecifying the sojourn time. Our results indicate a strong correlation between the es-
timated parameters, and that the chosen sojourn time-distribution has a strong effect on the accuracy
of the estimation. These findings shed a light on the seemingly discrepant results got by different
authors using the same data sets but different assumptions.
Keywords Screening programs · sensitivity · sojourn time · preclinical intensity.
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1 Introduction
The natural progression of a disease in the model pro-
posed by Shen and Zelen (1990) is regarded as a 3 state
model: individuals progress from a disease free state
Sf to the preclinical state Sp, when the disease has be-
come onset but is still asymptomatic, i.e. the person has
the disease but it does not show any symptoms. The fi-
nal state of the disease from our point of view is when
it manifests itself through clinical symptoms, thus it is
called the clinical state Sc.
Sf Sp Sc
Sojourn time is defined as the amount of time spent
in the preclinical state Sp, in other words it is the
time needed for the disease to show itself by means
of clinical symptoms. However, directly observing so-
journ time is not feasible as the exact time of onset is
unknown.The sojourn time is then estimated through
modelling, mostly by assuming it is a random variable
with a specified distribution, see e.g. Wu et al (2005),
Zelen and Feinleib (1969).
Early detection methods such as screening allows dis-
covering the disease before any symptoms appear.
Screening sensitivity, defined as the the probability of
detection given that the patient is in Sp, is crucial in de-
termining the efficiency of the screening program. A
case is said to be prevalent if its disease is detected by a
screen, and incident or interval if its disease is detected
by means of clinical symptoms between two screening
rounds. Note that while modelling the process, false
positive cases are not of interest, as further medical ex-
amination will reveal the absence of the disease.
The parameters of interest in such a process are the pre-
clinical intensity (probability of moving from the dis-
ease free state to the preclinical one during (t, t+ dt)),
the sojourn time and screening sensitivity. The estima-
tion of these parameters is essential to optimize screen-
ing intervals and to correct lead time bias. Lead time
bias is defined as the apparent increase in survival due
to early detection by means of screening.
The basis for disease progression models was set by
Zelen and Feinleib (1969) setting the foundations of the
theory of periodic screening, Porok (1976) extended the
theoretical background. Later, Shen and Zelen (1990)
introduced two models to estimate the parameters gov-
erning disease progression. The first describes stable
diseases that are assumed to have incidence and preva-
lence independent of time or age. The other incorpo-
rates time dependence of incidence and prevalence to
the model (these cases are called non stable diseases).
These models are built by deriving the probabilities of
cases being detected by screening or symptoms, this al-
lows the forming a likelihood function from which pa-
rameters can be estimated by classical methods such
as nonlinear maximization of the likelihood function, a
least squares approach or a Bayesian one.
Wu et al (2005) further extended the results by allow-
ing both the transition probability from the disease-free
state and the sensitivity to be age dependent. They as-
sume that the sojourn time follows a log-logistic dis-
tribution, the preclinical intensity has a log-normal dis-
tribution and the sensitivity is age dependent, the age
dependence is incorporated by assuming that the sensi-
tivity has a logistic function form.
Duffy et al (1995) proposed a Markov chain model as-
suming that the rate of transition between the preclin-
ical and the clinical state and the rate of transition be-
tween the disease free and the preclinical state are time
independent parameters to be estimated. In this model
the parameters can be estimated without control data.
In this paper we have constructed a simulator to imitate
the results of a breast cancer screening program. Us-
ing this tool our main goal was to check and compare
the performance of the models under different assump-
tions. So we simulated using different sojourn time dis-
tributions, age dependent sensitivity, and different inter-
screening times. The simulator allows recording of the
actual sojourn time, something which is not possible in
a real life scenario. This made it possible to compare
the estimated and the actual values.
The main aim of this paper is to see the effects of choos-
ing an incorrect distribution for the sojourn time, the
consequences of falsely assuming screening sensitivity
to be constant, study the influence of a higher inter-
screening interval and to check the reliability of the es-
timators under these assumptions.
The paper is organized as follows, Section 2 intro-
duces the mathematical part of the model proposed by
Wu et al (2005). Section 3 shows our estimates of the
process parameters based on simulated data. This sec-
tion is divided into 4 parts, the first corresponds to the
results obtained from the simulation based on an expo-
nential sojourn time, in the second we use simulations
from a gamma one, in the third from log-logistic so-
journ time and in the last one we show the performance
of the model when one uses an incorrect distribution
to model the sojourn time. In Section 4 we show the
reasons behind the discrepancy of estimates in the liter-
ature. Finally, the results are discussed in Section 5.
2 Model
We will use the general model proposed by Wu et al
(2005). Let us assume we have a cohort of individu-
als going through a screening program. Suppose that
they are stratified by age at program entry and that there
are K screens with an inter-screening interval ∆. Let
q(x) be the assumed p.d.f. of the sojourn time in the
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preclinical phase withQ(t) being the survivor function:
Q(t) =
∫
∞
t
q(x)dx , let Φ(t) be the sensitivity of the
screening exam at age t and define w(x) to be the pre-
clinical intensity.
Suppose that the first screen (k = 1) occurs at t0, define
ti = t0 +∆ · i the age of a person at the ith screen, and
let t−1 = 0. Then the probability of a person who is
aged t0 at the study entry to have cancer detected at the
first screen is given by
Φ(t0)
∫ t0
0
w(x)Q(t0 − x)dx
And for k = 2, . . . ,K , the probability of having cancer
detected by screening at screen k is given by:
Dk,t0 = Φ(tk−1)
[
k−2∑
i=0
[
(1− Φ(ti)) · · · (1 − Φ(tk−2))
∫ ti
ti−1
w(x)Q(tk−1 − x)dx
]
+
∫ tk−1
tk−2
w(x)Q(tk−1 − x)dx
]
(1)
The first term in the equation corresponds to those who
have been falsely screened as negative in the previous
screens and stayed in the preclinical state till the kth
screen. The second term corresponds to those moving
into the preclinical state in the previous screening inter-
val and stayed preclinical till the screen occurs.
The probability of a case becoming incident in the kth
screening interval can be derived similarly and is given
by:
Ik,t0 =
[
k−2∑
i=0
(1− Φ(ti)) · · · (1− Φ(tk−1))
∫ ti
ti−1
w(x)[Q(tk−1 − x)−Q(tk − x)]dx
]
+
∫ tk
tk−1
w(x)[1 −Q(tk − x)]dx
(2)
where the first term corresponds to those who have
moved to the clinical state before the kth screening in-
terval and were falsely screened and the second term
corresponds to those moving from Sf to Sc during the
kth screening interval.
Let us assume that in a screening program with K
screens for persons within the age range of [tmin, tmax]
using the simulated data, a total of nk,t0 persons aged
t0 at program entry are screened at screen k and out of
them sk,t0 persons were diagnosed by means of screen-
ing and rk,t0 persons were becoming incident in the k
th
screening interval. Then the likelihood is proportional
to:
L =
tmax∏
t0=tmin
K∏
k=1
I
rk,t0
k,t0
D
sk,t0
k,t0
(1−Dk,t0−Ik,t0)nk,t0−sk,t0−rk,t0
(3)
To get the maximum likelihood estimates we need to
specify parametric models and then they are obtained
through nonlinear minimization of the negative log-
likelihood. The variances of the parameter estimators
can be approximated using the observed Fisher infor-
mation matrix.
3 Results
Simulations were performed to imitate the results of a
breast cancer screening program. For that purpose we
simulated the progression of 10000 persons for each
age group (Nt0 = 10000) for t0 ∈ (tmin = 40, T =
64). However, instead of directly simulating screened
and symptomatic cases from a binomial distribution
with probabilities (1) and (2), we decided to develop
a simulator that assigns an actual sojourn time to each
case. As a result, we are able to directly compare the
actual sojourn time with the estimated one. For more
information about the simulation algorithm see the Ap-
pendix.
The distribution for the preclinical intensity is chosen
to be log-normal LN(µ, s2). The transition probabil-
ity of breast cancer to the preclinical state was esti-
mated by Lee and Zelen (1998). These were found to
be right skewed with a heavy tail, so the log-normal
distribution was chosen for having similar properties
(Wu et al (2005)). The defined values for the parame-
ters are µ = 3.971 and s = 2.8, so these values lead
to an average age of transition of around 54 years and a
standard deviation of 15 years.
Note that the preclinical intensity is a sub-density,
meaning that it is multiplied by the life time risk. E.g. 1
in 8 women will get breast cancer in the USA although
risk factors such as family history significantly raise the
risk (Madigan et al (1995)). We will use 15% in our
simulations:
w(t) =
0.15
ts
√
2pi
exp− ln(t− µ)
2
2s2
.
The choice of a slightly higher lifetime risk is for the
sake of simulation. A higher lifetime risk leads to more
cases progressing into the preclinical state and there-
fore increasing the number of screened and clinically
detected cases.
When minimizing the –log-likelihood, there is a possi-
bility of getting an unrealistic minimum that has a very
large sojourn time, a very low preclinical intensity and
a very low sensitivity, so some constraints are definitely
needed. For this purpose, the negative log likelihood
will be minimized under the constraints 3.5 ≤ µ ≤ 4.5
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and 0 < s ≤ 1. These constraints were derived by as-
suming that the mode age exp(µ−s2) of transition into
the preclinical state should lie within (30, 70) as well
as assuming that the average age of transition should
be less than 70 years: exp(µ + s
2
2 ) ≤ 70. Combining
these two assumptions leads to the bounds on µ and s
(Wu et al (2005)).
We chose to simulate progression based on 3 different
sojourn time distributions, namely :
1. An exponential distribution Exp( 1λ) having a
mean sojourn time 1λ = 2.5 years.
2. A gamma distributionΓ(α, β)where the shape
parameter is α = 6.25 and a rate parameter
β = 2.5 resulting in a mean sojourn time of
2.5 years and unit variance.
3. A log-logistic LL(ρ, κ) with a scale ρ = 4.7
and shape κ = 2.2 also leading to a mean
sojourn time around 2.37 years and approxi-
mately a unit variance.
The motivation behind choosing these distributions and
their parameters is that we wanted to create very dif-
ferent sojourn time distributions allowing us to see the
performance of the model under each chosen distribu-
tion.
Breast cancer’s screening sensitivity is known to be
increasing with age (Shapiro et al (1988)). Wu et al
(2005) choose to model this age dependence via a lo-
gistic function with parameters b0 and b1. As a result,
the sensitivity at age t is then given by
Φ(t) =
1
exp(−b0 − b1(t− t¯)) (4)
where t¯ is the average age of entry in the study. The
values defined for the simulation were b0 = 1.4 and
b1 = 0.05 resulting in a sensitivity between 68% for
those aged 40 and 93% for those aged 64. These val-
ues are based on the estimates of Smith et al (2012).
Note that b1 = 0 means that the sensitivity is constant
and independent of age. So, in order to see the effects
of falsely assuming the sensitivity to be constant, the
model will be run twice, first forcing b1 to be 0, and
then with no constraints on b1.
For each chosen sojourn time distribution, two screen-
ing programs were simulated for the same disease pro-
gression data, one with K = 5 screens and an inter-
screening interval of ∆ = 2 years, and the other with
K = 10 (∆ = 1 year), hence we can probe the effect of
a longer screening interval. The model is run with and
without the mentioned sensitivity constraint on each of
the data sets, resulting in 4 scenarios shown in Figure 1.
The function nlm in R is used to minimize the nega-
tive of the log-likelihood. The initial values for the
minimization are chosen at random, as follows. The
initial values for the sensitivity parameters b0 and b1
Disease
progression
data from
a chosen
sojourn time
Screening
program B
K = 10,∆ = 1
Scenario 4:
Model is run
fixing b1 = 0
Scenario 2:
Model is
run with no
sensitivity
constraints
Screening
program A
K = 5,∆ = 2
Scenario 3:
Model is run
fixing b1 = 0
Scenario 1:
Model is
run with no
sensitivity
constraints
Figure 1: Scenarios
are chosen from a uniform random variable U [0, 5] and
U [0, 0.5] respectively, these values result in a sensitiv-
ity between 0 and 99.99 % therefore have no effect on
the minimization. The preclinical intensity parameters
µ and s are chosen fromU [3.5] andU [0, 1] respectively,
the choice is based on a the constraints mentioned ear-
lier. The sojourn time parameters are initialized in the
following way: 1λ from U[0,15] in the exponential case,
α, β, κ and ρ are all initialized from a U [0, 10]. The
minimization is based on a Newton-Raphson method,
it calculates gradient at each step, if the gradient is ap-
proximately 0 that means that the current value is prob-
ably a solution. The algorithm was run multiple times
and it was noticed that the likelihood and the estimators
were converging to the same values.
3.1 Exponentially distributed sojourn time
The exponential distribution is the most commonly used
one in the literature. Table 3.1 shows the results, the
plots for the sojourn time and the sensitivity are shown
in the left panels of Figure 2.
The defined value for the mean sojourn time is λ= 2.5
years, the one observed from the simulated sample how-
ever is around 2.93 years. The structure of the model
itself leads to a bias which cannot be captured by the
exponential distribution. In fact, on the first screen, the
probability of a case to be detected by a screen is de-
termined by those who have moved into the preclinical
state before the program started and stayed preclinical
till the first screen. In other words, only cases with large
enough sojourn time will participate in the first screen,
as those who became clinical before that will not partic-
ipate. This explains the simulated sample mean sojourn
time of 2.93 years, since the estimate of the exponen-
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tial distribution parameter is known to be sensitive to
outliers.
Results observed from scenario 1 show a very high sen-
sitivity, it can be seen from the bottom part of Figure 2
that the sensitivity is increasing rapidly with age. The
estimated mean sojourn time is 2.2 years, which is less
than the actual sojourn time of 2.5 years. The preclini-
cal intensity estimators are exact in all scenarios, there
are small fluctuations but they are almost negligible.
Moving to scenario 3, which is based on the same run
of the screening program, but forcing the sensitivity to
be constant, we observe that the estimated sensitivity is
around 87% with a mean sojourn time of 2.554.
It can be noticed that the sojourn time and the sensi-
tivity have a strong negative correlation r = −0.83.
This is contradictory to assuming the sensitivity and
the sojourn time to be independent when constructing
the model. Screening acts as a censoring mechanism:
once a case is detected by a screen, the rest of its so-
journ time cannot be observed. This explains scenario
1 results, having high sensitivity with low sojourn time.
The same can also be seen in scenario 3 but on a lower
scale as the sensitivity is forced to be constant.
In scenario 2, estimates of the sensitivity parameters are
pretty accurate, with a mean sojourn time of around
2.705 years, the estimates are good showing that the
model performs well in this scenario. We may compare
these values to the results from scenario 4 having an
estimated constant sensitivity of around 82%, and a so-
journ time of 2.722 years. It can be noticed that when
using constant sensitivity, the estimated one is around
the average sensitivity. However, as there is a strong
correlation with the sojourn time, choosing to model an
age dependent sensitivity using a constant one causes
the mean sojourn time to become age dependent. In
other words, as younger cases have a lower sensitiv-
ity, this creates the false impression that young patients
have a higher mean sojourn time, and the older ones
have a lower mean sojourn time as they have a higher
sensitivity, although the mean sojourn time is the same
for both.
Next, we compare the results for different inter-
screening intervals. Naturally, a larger inter-screening
interval means that there are fewer opportunities for an
individual to participate in a screening exam, meaning
that it will lead to a high number of clinically detected
(interval) cases. The model preserves a good fit in one
of two ways, the first is by returning a high sensitivity
estimate and a low sojourn time meaning that cases stay
a short time in the preclinical state but participation in
a screen leads to detection with a high probability. The
second is by combining a high sojourn time estimate
with a low sensitivity, meaning that cases will stay for
a longer time in the preclinical state, therefore having
multiple chances to participate in a screen, with screens
having a low probability of detection. These can be ob-
served as multiple local minima of the negative log like-
lihood function.
3.2 Gamma distributed sojourn time
Simulating a screening program based on a gamma dis-
tributed sojourn time seemed natural due to its relation
with the exponential distribution. The results of the sce-
narios are shown in Table 2 with plots for the sojourn
time density and sensitivity shown in the middle panels
of Figure 2.
The first observations are the high values for the sojourn
time parameters α and β in all scenarios. The upper
part of Figure 3 shows the negative of the log likeli-
hood while moving on the span of α = 2.5β starting
from α = 1 and β = 0.6 and updating α by adding 1
and β by adding 0.4 maintaining the mean sojourn time
α/β = 2.5 however decreasing the variance αβ2 . It was
noticed that for large α and β, corresponding to a low
variance and a sojourn time which is very dense around
its expected value, the likelihood is almost constant and
close to the log-likelihood at the maximum. Therefore,
these large values of α and β will all fall within the ac-
ceptable region leading to multiple maxima of the like-
lihood. This shows a serious flaw in the model. Al-
though it is still able to capture the mean sojourn time
under correct assumptions, it is completely unable to
capture the variance of the sojourn time, in fact, the
model gives equal likelihood for different sojourn time
densities which are very dense around the mean. The
bottom part of Figure 3 shows multiple densities which
have equal likelihood according to the model.
Results also show that the observed Fisher information
matrix is not positive definite: it was found that two
eigenvalues are very close to 0. Therefore, we are not
able to estimate variances of our estimators. This is
likely caused by the existence of multiple minima and
the strong correlation between the parameters.
That being said, one still gets good estimates for the
mean sojourn time and the sensitivity in scenario 2,
while forcing the sensitivity to be constant gives slightly
worse results in scenario 4. In scenarios 1 and 3, it is
noticed that one gets a lower estimate of sensitivity and
a higher mean sojourn time. This is due to the larger
inter-screening interval in these scenarios.
3.3 Log-logistic distributed sojourn time
The log-logistic distribution was suggested by Wu et al
(2005) as its survivor and hazard functions have rela-
tively simple analytic forms. E.g. the survivor function
of the log-logistic distribution is given by
Q(x) =
1
1 + (x/κ)ρ
.
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Table 1: Estimated sensitivity parameters (b0 and b1), preclinical intensity parameters (µ and s) and sojourn time
parameter (λ) – data generated by an exponentially distributed sojourn time
Parameters b0(SD) b1(SD) µ(SD) s(SD) 1/λ (SD)
Actual 1.4 0.05 3.971 0.268 2.5
S 1 4.238(1.116) 0.302(0.109) 3.974(0.005) 0.269(0.004) 2.226(0.057)
S 2 1.442(0.144) 0.052(0.011) 3.972(0.006) 0.276(0.004) 2.705(0.107)
S 3 1.941(0.415) 0(NA) 3.975(0.006) 0.272(0.005) 2.554(0.192)
S 4 1.462(0.139) 0(NA) 3.975(0.006) 0.273(0.004) 2.722(0.107)
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Figure 2: Plots for actual and estimated sojourn time density (top) and sensitivity (bottom) in all scenarios – data
generated from exponential distribution(left), gamma distribution(middle), log-logistic(right)
Table 2: Estimated sensitivity parameters (b0 and b1), preclinical intensity parameters (µ and s) and sojourn time
parameters (α and β) – data generated from a gamma distributed sojourn time
Scenario b0 b1 µ s α β α/β
Actual 1.4 0.05 3.971 0.268 6.25 2.5 2.5
S 1 1.221 0.0382 3.972 0.285 156.693 50.047 3.131
S 2 1.447 0.039 3.971 0.276 3929.657 1458.852 2.694
S 3 1.219 0 3.977 0.287 133.102 41.027 3.244
S 4 1.401 0 3.975 0.277 1625.477 581.666 2.794
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dated by adding 1 to α and 0.4 to β at each index point
(constant mean sojourn time and decreasing variances),
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The results of the scenarios are displayed in Table 3,
plots for the sensitivity and sojourn time are shown in
Figure 2.
The observed results are similar to the gamma case, the
observed Fisher information matrix is also not positive
definite, although only one eigenvalue is very close to
0. Scenario 2 and 4 seem to perform well, although sen-
sitivity estimates seem to be a bit high. The effect of a
high inter-screening interval is amplified here, a higher
inter-screening interval either leads to a high sensitivity
with a lower sojourn time (as in scenario 1) or a higher
sojourn time and a lower sensitivity (as in scenario 2).
3.4 Misspecified sojourn time
One of the main question that this paper answers is what
will happen when one chooses an incorrect distribution
to model the process. For this purpose, the model is run
on the data generated by a known distribution, while
intentionally using another distribution to model the so-
journ time. In other words, the form of Q(x) is incor-
rectly chosen to see the effects, this is a realistic situa-
tion, as in practice we do not know the data generating
process. The models are all run on the data generated
by the screening program consisting of 10 screens with
∆ = 1 with the only constraints being the ones on the
preclinical intensity.
Let us start with the data generated from an exponen-
tially distributed sojourn time. The results of fitting dif-
ferent distributions are shown in the top block of Table
4. Using the gamma distribution to model exponentially
distributed sojourn time returns α = 1.269 (SD =
0.0615) and β = 0.499 (SD = 0.354) giving a mean
sojourn time of 2.54, we found that fitting a gamma dis-
tribution results in a better fit and more accurate esti-
mates than actually using the exponential one. This is
likely due to the ability of the gamma distribution to
handle the bias caused by the first screen which was
mentioned earlier as well as its ability to capture the ex-
ponential distribution (by the parametrization α = 1).
Choosing to model an exponential sojourn time with
a log-logistic distribution returns a likelihood of -
69,473.6, significantly higher than the likelihood of us-
ing the exponential distribution. The mean sojourn time
estimate is 2.74 years, close to the one estimated by us-
ing an exponential distribution. The higher likelihood
does not necessarily mean that using the log-logistic
distribution is better, as the log-logistic distribution is
a two parameter family, it is able to cope with the first
screen bias and the exponential one can’t therefore the
higher likelihood. Yet when comparing the densities,
the log-logistic density is very far from the actual den-
sity.
Moving on to the data generated from a gamma dis-
tributed sojourn time, the results are displayed in the
middle block of Table 4. Choosing to model a gamma
distributed sojourn time by an exponential distribution
to model results in a very high sojourn time estimate
of 4.67(0.172) years and it was also noticed that both
sensitivity and preclinical intensity parameters are also
high with high variances. This is highly problematic as
the exponential distribution is the most used one in the
literature.
It also seems that using the log-logistic distribution re-
turns a result which is almost identical to the gamma
one, with parameters ρ = 2.693 and κ = 85.455
both leading to a sojourn time which is extremely dense
around the mean sojourn time.
For data generated from a log-logistic sojourn time, the
results are displayed in the bottom block of Table 4. In
this case, choosing to model the sojourn time by an ex-
ponential distribution results in inaccurate parameter es-
timates as well, with the mean sojourn time being 4.168
years – much higher than the real mean sojourn time.
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Table 3: Estimated sensitivity parameters (b0 and b1), preclinical intensity parameters (µ and s) and sojourn time
parameters (ρ and κ) – data generated from a log-logistic distributed sojourn time
Scenario b0 b1 µ s ρ κ MST
Actual 1.4 0.05 3.971 0.268 2.2 4.7 2.372
S 1 5.623 0.396 3.969 0.256 1.785 15.506 1.797
S 2 1.814 0.054 3.969 0.266 2.251 71.939 2.252
S 3 1.614 0 3.974 0.274 2.633 23.187 2.641
S 4 1.852 0 3.9713 0.264 2.238 73.774 2.239
Table 4: Estimated sensitivity parameters (b0 and b1), preclinical intensity parameters (µ and s) and mean sojourn time
(MST) obtained by using different forms of Q(x) (different choices of sojourn time)
Exponential sojourn time
Q(x) Log likeli-
hood
b0 b1 µ s MST
Actual 1.4 0.05 3.971 0.268 2.5
Exponential -69,485.81 1.442(0.144) 0.052(0.011) 3.972(0.006) 0.276(0.004) 2.705
Gamma -69,471.08 1.256(0.135) 0.033(0.009) 3.969(0.005) 0.269(0.004) 2.541
Log-logistic -69,473.60 1.316(0.137) 0.025(0.008) 3.965(0.005) 0.267(0.004) 2.744
Gamma sojourn time
Actual 1.4 0.05 3.971 0.268 2.5
Exponential -66,191.00 1.703 (0.138) 0.119 (0.013) 4.028 (0.008) 0.330 (0.005) 4.677 (0.172)
Gamma -65,235.42 1.447 0.039 3.971 0.276 2.694
Log-logistic -65,235.42 1.447 0.039 3.971 0.276 2.694
Log-logistic sojourn time
Actual 1.4 0.05 3.971 0.268 2.373
Exponential -65,928.12 2.080 (0.214) 0.140 (0.021) 4.026 (0.007) 0.319 (0.005) 4.168 (0.161)
Gamma -64,781.29 1.814 0.055 3.97 0.267 2.252
Log-logistic -64,781.30 1.814 0.055 3.97 0.267 2.252
Modelling with a gamma distribution returns very large
alpha and beta values resulting in a mean sojourn time
of 2.252 years. The estimates of preclinical intensity
and mean sojourn time are very close to the real ones.
4 Consequences for previous results
Table 5 shows the estimates of the mean sojourn
time and the sensitivity in some famous clinical trials.
The health insurance plan of greater New York (HIP)
and the clinical trial of Edinburgh Shen and Zelen
(2001), the first and the second Canadian National
Breast Screening Study (CNBSS1&2)Miller, A.B. et al
(1992), Miller, A.B. et al (1992). The CNBSS studies
were separated by age, the first for those aged 40–49
at entry and the second for those aged 50–59 at en-
try, and the Norwegian Breast Cancer Screening Pro-
gram (NBCSP). One immediately notices the variation
between the estimates confirming the sensitivity of the
model to the underlying approach, in fact one can no-
tice that there are completely different estimates based
on the same data set.
Chen et al (2010) used a stable disease approach and
used the gamma distribution to model the sojourn time
of breast cancer. They applied their model on the
CNBSS data. They modeled the 40—49-year-old and
50—59-year-old cohorts separately, resulting in esti-
mates for the sensitivity for the age groups as 0.70 and
0.77 respectively and for the mean sojourn time as 2.55
years and 3.15 years respectively. The approach they
used assumed the sensitivity and the preclinical inten-
sity both to be constants. The main issue with their ap-
proach is that they chose to bound the shape and the
rate parameter of the sojourn time using uniform priors.
This may lead to convergence to a local maximum of
the likelihood within the chosen bounds. The same is
done by Wu et al (2005), who used constraints on the
sojourn time, the preclinical intensity, as well as the
sensitivity when maximizing the likelihood. In other
words, they run MCMC simulation on a bounded area
to find a local maximum. Although the constraints on
the preclinical intensity are natural, constraining the so-
journ time has no real justification, especially since the
constraints on κ and ρ essentially are also constraints on
the variance of the sojourn time, something which there
is no prior information about. It was shown earlier that
the model maintains a constant likelihood when the ra-
tio shape/rate is close to the mean sojourn time.
Now regarding the conflicting results of the CNBSS1
studies, Shen and Zelen (2001) estimated the sensitiv-
ity for Mammography(M) and physical examination(P)
independently, their mean sojourn time estimate for the
CNBSS1 trial is 1.9 years, significantly lower than the
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Table 5: Sojourn time and sensitivity estimates(M: mammography , P: physical exam ) for some clinical trials
Mean sojourn time sensitivity
HIP ( Shen and Zelen (2001)) 2.5 M:0.39 P:0.47
Edinburgh ( Shen and Zelen (2001)) 4.3 M:0.63, P:0.40
CNBSS1 ( Shen and Zelen (2001)) 1.9 M:0.61, P:0.59
CNBSS2 ( Shen and Zelen (2001)) 3.1 M:0.66, P:0.39
CNBSS1 (Chen et al (2010)) 2.55 0.7
CNBSS2 (Chen et al (2010)) 3.15 0.77
NBCSP for the age group [50,59] (Weedon-Fekjaer et al (2005)) 6.1 0.58
NBCSP for the age group [60,69] (Weedon-Fekjaer et al (2005)) 7.9 0.73
estimate of Chen et al (2010) of 2.55 years, they chose
to model the sojourn time using a gamma distribution,
which is possibly the reason behind the difference in the
estimates.
A two parameters (entry–exit) Markov chain model is
used by Duffy et al (1995), assuming that the incidence
rate λ1 and the rate of transition from the preclinical
state to the clinical one λ2 are both constants. When
this method is applied to the data from the Swedish two-
county study of breast cancer screening in the age group
70-74, the resulting estimate for the mean sojourn time
is 2.3 years. Although the model is very flexible in the
sense that interval data is not needed, the constant in-
cidence rate λ1 implies that the amount of time spent
in the disease free state is an exponential random vari-
able, which is not likely to hold true. In addition to that,
the entry–exit model can have multiple feasible maxi-
mum likelihood estimates, the extreme case would be a
very low preclinical rate combined with a very large so-
journ time and a very low sensitivity, applying multiple
bounds while maximizing the likelihood is also risky
as it may lead to a local maximum within the chosen
bounds, possibly excluding the real solution.
Weedon-Fekjaer et al. used a weighted non-linear
least-square regression estimates based on a three step
Markov chain model, then performed sensitivity anal-
ysis to determine the possible impact of opportunistic
screening between regular screening rounds. Mean so-
journ time and sensitivity were estimated by non-linear
least square regression, using number of cancer cases
at screening and in the interval between screening ex-
aminations. Mean sojourn time was estimated as 6.1
(95% confidence interval [CI] 5.1-7.0) years for women
aged 50-59 years, and 7.9 year (95% CI 6.0-7.9) years
for those aged 60-69 years, sensitivity was estimated as
58% (95% CI 52-64 %) and 73 % (67-78 %), respec-
tively. There are multiple issues with these estimates:
we suspect that the reason of the high sojourn time es-
timate is the consequence of the choice of the sojourn
time distribution, as we have shown earlier, using the
exponential distribution to model the sojourn time if it
is not actually exponential results in a very high sojourn
time estimate. Their findings also indicate that sensitiv-
ity is lower than in other programs as well as a higher
mean sojourn time, we believe it to be a direct conse-
quence of the correlation between the two.
To recreate their results, we ran a simulation for
200,000 initial participants, with the preclinical inten-
sity of 200 per 100000 person years, we simulated a
screening program consisting of 5 screens with 2 years
inter-screening interval. However, we simulated the
sojourn time from a gamma distribution γ(6.25, 2.55)
having a mean sojourn time of 2.5, screens were simu-
lated based on their sensitivity estimate of 58%.
After generating the data, we modelled the sojourn
time using an exponential distribution (λ) instead of a
gamma one. We then ran the minimization of the -log-
likelihood having fixed the sensitivity and the preclin-
ical intensity, in other words, we are only minimizing
with respect to the sojourn time parameter λ. The result-
ing mean sojourn time estimate was 6.46 years, close to
their estimate, but quite far from the real mean sojourn
time.
5 Discussion
We can state that the current models are very sensitive
to the underlying assumptions. One should take great
care when using such an approach and multiple trials
with different models are needed before getting results.
Summarizing, using the exponential distribution proved
to be quite risky as it could result in a much highermean
sojourn time estimates if the data came from another
model. It is suggested to use the gamma distribution in-
stead, because it had better properties, not only for the
gamma, but also for the exponential model. However
multiple minima may exist and it can happen that the
model cannot capture the variance of sojourn time. The
log-logistic and the gamma distributions behave simi-
larly and models return quite similar results. There is a
strong negative correlation between sensitivity and so-
journ time, assuming sensitivity to be constant forces
the mean sojourn time to be age dependent as a conse-
quence of the correlation between them. Higher inter-
screening intervals result in less accurate estimates, ei-
ther by a high sojourn time and a low sensitivity or the
opposite. In the future, we plan to model the process in-
corporating tumor sizes and speed of growth. This may
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introduce a good constraint on the sojourn time, leading
to more stable and accurate results.
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Appendix
A Simulation Algorithm
Let us first introduce some notations: denote by a the
99.99% quantile of the sojourn time, Let 1/h be the
time discretization constant, n1,t0 the number of indi-
viduals who are aged t0 at program entry (first screen).
Let t0,min and t0,max be the minimum and the maxi-
mum age of the target sample at the first screen. Also
denote by Vt0 the number of preclinical individuals at
t0 and byHt0 = n1,t0 − Vt0 the number of disease free
individuals at t0. Denote by t the individual’s age, β(t)
be the sensitivity of the screening exam at age t. Let
w(t) be the probability of moving from the disease free
state to the preclinical one during (t, t+ dt) .
A.1 Disease progression
The first step of the simulation is to determine the initial
state of participants, (Ht0 and Vt0 )
for each t0 = tmin, tmax and for a predefinedNt0 .
1. Assume all individuals are disease free when
aged t0 − b
2. Discretize the interval [t0 − b, t0) into b ∗ h
intervals of width 1/h
3. Denote by pi,h =
∫ t0−b+(i+1)/h
t0−b+i/h
w(x)dx the
probability of moving to the preclinical state
in the interval [t0− b+ i/h, t0− b+(i+1)/h)
4. For i = 0, 1, . . . , (b ∗ h − 1) simulate
progression into the preclinical state by a
Bernoulli(pi,h) random variable and store it
in an array xi
• If∑b∗h−10 xi = 0 thenHt0=Ht0 + 1
• If ∑b∗h−10 xi ≥ 1 store the age tp :=
t0 +min{i : xi = 1} ∗ h in which the in-
dividual became preclinical and generate
a random sojourn time J from the chosen
sojourn time distribution and assign it.
5. If tp+J ≤ t0 the case is discarded as it turned
out to be clinical before the screening program
started.
6. If tp + J > t0 then Vt0=Vt0 + 1 and store tp,
J , and t0
7. Stop when Vt0 + Ht0 = Nt0 and repeat the
same process for t0 = t0 + 1
Simulation of progression into the preclinical state dur-
ing the screening program is done similarly, however
checking if tp + J < t0 is not required and any case
becoming preclinical is stored.
A.2 Screening
Assume that all individuals go through all K screens.
Note that this assumption can be released by simple ran-
dom sampling out of both healthy and preclinical cases.
For a screening program with K screens and an inter-
screening time ∆ years the duration of the program is
K ∗∆ years.
For each t0 = tmin, . . . , tmax and for those who have
moved into the preclinical state before t0 define an in-
dicator variable S where S = 1 indicates detection
by screening and S = 0 indicates clinical detection.
Also introduce variable C = 1, . . . ,K which indicates
cancer is detected in screen C. Note that false posi-
tive cases are not of interest as it is assumed that fur-
ther medical examination will show the absence of the
disease. As a result, screening simulation is run only
for already preclinical cases. Simulation of screens
is done by the following algorithm: start by setting
t = t0, u = 1
1. The detection of cancer by a screen is gener-
ated from a Bernoulli(β(t))
2. If cancer is detected by the screen then set S =
1 and C = u.
3. If the cancer is not detected by the screen then
• If tp+J < t+1 then the case has become
clinical, so store S = 0 and C = u
• If tp + J > t + 1 then update t = t + 1
and u = u+ 1 and return to step 1
4. If the program ends and the case is not de-
tected then the case was neither detected by
screening nor by clinical symptoms therefore
there was no real information recorded, the
case is then just recorded as a person taking
a set of screening exams.
For cases developing cancer during the screening pro-
gram, let us denote i = 1, . . . ,K − 1 the interval in
which the case became preclinical. One must check if
they moved into the preclinical state before the next
screen. The simulation is done in a similar way to
the stated algorithm, however the number of remaining
screens isK − i.
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